This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wu, C.-C. Articles by Strong, L. C. Search for Related Content PubMed PubMed Citation Articles by Wu, C.-C. Articles by Strong, L. C.

Joint Effects of Germ-Line p53 Mutation and Sex on Cancer Risk in Li-Fraumeni Syndrome

¹ Department of Epidemiology and ² Section of Clinical Cancer Genetics, Department of Molecular Genetics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Chih-Chieh Wu, Department of Epidemiology, Unit 1340, The University of Texas M.D. Anderson Cancer Center, 1155 Pressler Street, CPB4.3594, Houston, TX 77030. Phone: 713-745-3977; Fax: 713-792-8261; E-mail: ccwu{at}mdanderson.org.

Germ-line p53 mutations have been identified in most families with Li-Fraumeni syndrome (LFS). For germ-line p53 mutation carriers, there is considerable variability with respect to age of cancer onset and tumor type, suggesting that additional genetic effects influence the clinical severity and tumor spectrum. To identify factors that might contribute to the observed heterogeneity in time to onset, we used segregation analysis to analyze the joint effects of germ-line p53 mutations and risk modifier(s) on cancer incidence. We studied 159 kindreds, ascertained through probands who had been diagnosed with childhood soft-tissue sarcoma before 16 years of age, survived >3 years after diagnosis, and treated at The University of Texas M.D. Anderson Cancer Center (Houston, TX) from 1944 to 1975. This unique cohort has been followed systematically for >20 years and has had germ-line p53 mutation testing in probands and extended family members. The analyses revealed that germ-line p53 mutations and sex had significant effects on cancer risk: men with p53 mutations had 151-fold higher odds of developing cancer than did those without mutations [95% confidence interval (95% CI), 60-380], and women with p53 mutations had 1,075-fold higher odds than did those without mutations (95% CI, 358-3,229) and 7.1-fold higher odds of having cancer than did men with mutations (95% CI, 2.5-20.3). These findings provide quantitative cancer risk assessments for LFS families. (Cancer Res 2006; 66(16): 8287-92)

This article has been cited by other articles:

				A. J Clarke and C. Gaff Challenges in the genetic testing of children for familial cancers Arch. Dis. Child., November 1, 2008; 93(11): 911 - 914. [Full Text] [PDF]

				U. Tabori and D. Malkin Risk Stratification in Cancer Predisposition Syndromes: Lessons Learned from Novel Molecular Developments in Li-Fraumeni Syndrome Cancer Res., April 1, 2008; 68(7): 2053 - 2057. [Abstract] [Full Text] [PDF]

				D. D. Orsted, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population J. Exp. Med., June 11, 2007; 204(6): 1295 - 1301. [Abstract] [Full Text] [PDF]